普拉西斯精准医疗

最新新闻

• 评级变动
  A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $462 to $800
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Raymond James Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Announces Target Price $945
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  Oppenheimer Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $650
  \u5e02\u573a\u8d44\u8baf · 2026/8/18
• H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,201
  \u5e02\u573a\u8d44\u8baf · 2026/10/6
• JonesTrading Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $534
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $441 to $1,201
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• Needham Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $582
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• Goldman Sachs Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $575
  \u5e02\u573a\u8d44\u8baf · 2026/8/21
• 评级变动
  LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $719
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $754
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• 评级变动
  RBC Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $449
  \u5e02\u573a\u8d44\u8baf · 2026/7/11
• 评级变动
  Guggenheim Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $800
  \u5e02\u573a\u8d44\u8baf · 2026/6/30
• 评级变动
  Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,200
  \u5e02\u573a\u8d44\u8baf · 2026/7/13
• 评级变动
  H.C. Wainwright Sticks to Its Buy Rating for Praxis Precision Medicines (PRAX)
  TipRanks · 2026/8/7
• 评级变动
  Goldman Sachs Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $575
  \u5e02\u573a\u8d44\u8baf · 2026/8/20
• 评级变动
  Jefferies Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $550
  \u5e02\u573a\u8d44\u8baf · 2026/6/30
• 公司公告
  Praxis Precision Medicines: Praxis Precision Medicines, Inc. - Reverse Split Option Symbol: PRAX New Symbol: PRAX1
  OCC · 2023/11/28
• 评级变动
  Jefferies Initiates Praxis Precision Medicines(PRAX.US) With Buy Rating, Announces Target Price $447
  \u5e02\u573a\u8d44\u8baf · 2026/7/14
• 评级变动
  LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Cuts Target Price to $719
  \u5e02\u573a\u8d44\u8baf · 2026/6/30
• Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Prime Medicine, Inc. (PRME)
  TipRanks · 2026/10/6

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。